Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659126 · ClinicalTrials.gov registry record · Phase 2
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00659126 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00659126, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase II trial studies how well magnetic resonance imaging (MRI) using contrast imaging agent ferumoxytol works in comparison to standard imaging agent gadolinium in measuring tumors in patients undergoing treatment for brain tumors or other tumors that have spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose disease and find out how far the disease has spread. MRI scans use radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. The contrast imaging agent ferumoxytol consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It is highly visible on the MRI, and may help visualize the blood flow going through the tumor better than gadolinium can. Using a more sensitive and faster 7 Tesla (7T) magnet MRI in conjunction with a contrast imaging agent may provide a better way to measure tumors than the 3 Tesla (3T) magnet MRI in patients with brain tumors.
Interventions
- DRUG Ferumoxytol
- DRUG Gadolinium
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- PROCEDURE 3 Tesla Magnetic Resonance Imaging
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-11-16 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659126
The ClinicalTrials.gov registry entry for NCT00659126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ferumoxytol is the first listed.
NCT00659126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659126 about?
NCT00659126 is a clinical study titled "Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors". This phase II trial studies how well magnetic resonance imaging (MRI) using contrast imaging agent ferumoxytol works in comparison to standard imaging agent gadolinium in measuring tumors in patients undergoing treatment for brain tumors or other tumors that have spread to the brain. Diagnostic proc...
What is the current status of trial NCT00659126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-11-16. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT00659126?
The interventions under investigation include: Ferumoxytol (DRUG), Gadolinium (DRUG), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), 3 Tesla Magnetic Resonance Imaging (PROCEDURE), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00659126?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.